- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 54 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
| 01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
| 27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 153 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 133 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 120 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
| 25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 160 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 21.02. | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
| 21.02. | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
| 21.02. | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 250 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 331 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 243 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 338 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 859 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,493 | -1,28 % | Teladoc Health, Inc. (TDOC): Among the Best Growth Stocks Under $10 to Buy Right Now | ||
| HIMS & HERS HEALTH | 53,60 | -2,12 % | Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month | ||
| BECTON DICKINSON | 153,40 | +0,20 % | BD files patent infringement lawsuit against Baxter over infusion pump tech | ||
| DEXCOM | 76,93 | -0,67 % | DexCom Promotes COO Jacob Leach To Additional Role Of President | WASHINGTON (dpa-AFX) - DexCom, Inc. (DXCM) announced Tuesday the promotion of Jacob Leach to president, in addition to his current role as chief operating officer, which he has held since 2022.With... ► Artikel lesen | |
| INVITAE | - | - | Ex-Invitae Spinoff Relaunches as Citizen Health, Picks Up $14.5M in Seed Funding | ||
| ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| RYMAN HEALTHCARE | 1,209 | -4,35 % | XFRA AUFHEBUNG VON AMTS WEGEN IN NZRYME0001S4 | Folgende Geschaefte in der ISIN NZRYME0001S4, Wertpapier-Name: RYMAN HEALTHCARE GRP LTD, wurden von Amts wegen aufgehoben:Datum Zeit Volumen Preis24.02.2025 08:02:33 100 2.388 ► Artikel lesen | |
| CYTOSORBENTS | 0,697 | -6,82 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| SENSEONICS | 0,513 | +0,04 % | Senseonics targets $34M-$38M revenue in 2025 with Eversense 365 expansion | ||
| STAAR SURGICAL | 15,485 | -8,43 % | Stifel maintains $20 target, Buy rating on STAAR Surgical stock | ||
| EKSO BIONICS | 0,352 | -12,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| INTERPACE BIOSCIENCES | 0,690 | 0,00 % | Interpace Biosciences GAAP EPS of $0.06, revenue of $11.5B | ||
| INSPIRE MEDICAL SYSTEMS | 136,45 | -2,29 % | Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook | Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire... ► Artikel lesen |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,012 Euro und damit -30,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.